Pressor Response to Intravenous Tyramine in Healthy Subjects After Safinamide, a Novel Neuroprotectant With Selective, Reversible Monoamine Oxidase B Inhibition

Authors:
  • CCCarla Caccia
    Carla Caccia
  • AMAntonio Marzo
    Antonio Marzo
  • RMRoberto Maj
    Roberto Maj
  • RFRuggero G. Fariello
    Ruggero G. Fariello
Publisher website
Google Scholar
Abstract
Safinamide is a novel neuroprotectant combining sodium and calcium channel blocking properties with selective, reversible monoamine oxidase type B (MAO B) inhibition. Phase 1 studies have demonstrated that in healthy volunteers, the ED50 (a dose that inhibits enzyme activity by 50% in 50% of treated subjects) for MAO B inhibition is 87.5 μg/kg/day orally, and that no MAO A inhibition occurs after 10-mg/kg oral dosing. To assess the risk of inducing the “cheese effect,” the effect of safinamide and placebo on the pressor response to tyramine was investigated in a group of healthy male volunteers. The study was an open, single-dose placebo-controlled trial with the 2 treatments in sequence. An increase of 30 mm Hg systolic blood pressure was obtained by intravenous tyramine administered by 0.5-mg incremental boluses injected at 15-minute intervals. The amount of tyramine necessary to achieve such a blood pressure increase was the same after the safinamide 2-mg/kg oral load compared with placebo. These results suggest that dietary restrictions for food with high tyramine content should not be required under safinamide treatment.

This publication has 21 references indexed in Scilit: